Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Continuing Anti PD-1 Therapy Beyond RECIST Progression

January 12th 2016

Latest Advances in Multiple Myeloma Treatment

January 12th 2016

Potential Role of Daratumumab in Multiple Myeloma

January 12th 2016

FDA Labels of New Multiple Myeloma Agents

January 12th 2016

Using Pomalidomide in Multiple Myeloma

January 12th 2016

Applying New Multiple Myeloma Agents to Practice

January 12th 2016

Elotuzumab and Ixazomib in Multiple Myeloma

January 12th 2016

Significance of the ENDEAVOR Trial in Multiple Myeloma

January 12th 2016

Managing Relapsed Disease in Multiple Myeloma

January 12th 2016

Consolidation and Maintenance Therapy in Multiple Myeloma

January 12th 2016

Transplant-Eligible Patients in Multiple Myeloma

January 12th 2016

Treating Multiple Myeloma in Elderly Populations

January 12th 2016

Treatment Regimens for Transplant Ineligible Myeloma

January 12th 2016

Managing Smoldering Myeloma

January 12th 2016

Defining High-Risk Multiple Myeloma

January 12th 2016

Molecular Pathogenesis of Multiple Myeloma

January 12th 2016

Dr. Moreau on Tourmaline-MM1 Study for Multiple Myeloma

January 7th 2016

Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.

Expert Discusses Promising Pembrolizumab Triplet in Advanced Myeloma

January 5th 2016

Jesus San Miguel, MD, PhD, discusses a phase I study examining pembrolizumab added to lenalidomide and low-dose dexamethasone in patients with heavily pretreated relapsed/refractory multiple myeloma, while emphasizing the need for further follow-up.

Dr. Hofmeister on Reolysin Combined With Carfilzomib for Multiple Myeloma

January 4th 2016

Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

Clinical Decision Making in Multiple Myeloma for the Transplant-Eligible Patient–Upfront Transplant Versus Maintenance Therapy

December 31st 2015

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.